Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Boehringer discontinues brigimadlin while others continue to struggle.
The group could soon provide clarity on CTX112’s regulatory path.
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
The THIO-104 study listing is live, along with questions about funding the trial.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
